Results 101 to 110 of about 429,043 (216)

Etanercept in axial spondyloarthritis

open access: yesChinese Medical Journal, 2022
Gui Luo, Jian Zhu, Lishao Guo
openaire   +3 more sources

European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Updated S2k hidradenitis suppurativa (HS) guidelines provide expert consensus on diagnosis, assessment and comorbidities. Expanded substantially since the 2015 version, they reflect rapid growth in HS literature and aim to improve generalist‐level patient care through evidence‐informed, consensus‐based guidance.
G. B. E. Jemec   +36 more
wiley   +1 more source

Axial Spondyloarthritis Flares — Whatever They Are [PDF]

open access: yesThe Journal of Rheumatology, 2017
Of the many things that people with ankylosing spondylitis (AS)/axial spondyloarthritis (axSpA) would like the medical profession to achieve for them, among the most pressing is providing effective ways of managing or preventing flares. Flares present a difficult set of problems: They are not predictable and often occur when contact with a physician or
openaire   +2 more sources

Autoimmunity and Periodontitis

open access: yesJournal of Periodontal Research, EarlyView.
In a microbe‐driven inflammatory environment, peptidyl‐arginine deiminase (PAD) enzymes from neutrophils and Porphyromonas gingivalis citrullinate both microbial and self‐antigens. B cell presentation of citrullinated or self‐mimicking epitopes activates T cells that assist B cells in antibody isotype switching, affinity maturation, epitope spreading ...
Massimo Costalonga   +2 more
wiley   +1 more source

Case Report: Achilles enthesitis as the presenting clue to occult sacroiliitis in hidradenitis suppurativa

open access: yesFrontiers in Medicine
Hidradenitis suppurativa is increasingly recognized as a systemic inflammatory disease with an established overlap with spondyloarthritis. Axial spondyloarthritis is usually suspected when patients report inflammatory back pain, which remains the entry ...
Mohamed Bedaiwi
doaj   +1 more source

Knockdown of mitotically associated long non‐coding RNA dysregulates endothelial functions, transcriptome and proteome

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Downregulation of mitotically associated long non‐coding RNA (MANCR) disturbs transcriptome and proteome in endothelial cells, possibly leading to endothelial and vascular dysfunction in preeclampsia. Abstract Preeclampsia (PE) is a hypertensive disorder during pregnancy, which is characterized by a wide spectrum of endothelial ...
Si‐Yan Zhang, Chi Zhou, Jing Zheng
wiley   +1 more source

Real‐World Trends in Prenatal Antirheumatic Drug Utilization in Ontario, Canada: A Cross‐Sectional Time‐Series Analysis

open access: yesArthritis Care &Research, Volume 78, Issue 11, Page 1801-1810, November 2026.
Objective This study aimed to describe real‐world trends in preconception and prenatal use of antirheumatic drugs among pregnant individuals with rheumatic diseases in Ontario, Canada. Methods We conducted a time‐series analysis using repeated cross‐sectional data to examine annual patterns of disease‐modifying antirheumatic drug (DMARD) use among ...
Shenthuraan Tharmarajah   +6 more
wiley   +1 more source

PO:01:011 | Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies

open access: yesReumatismo
Purpose of the Work. Bimekizumab (BKZ), a monoclonal antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has shown sustained efficacy and safety to Week (Wk)104 in patients (pts) across the full spectrum of axial ...
Società Italiana di Reumatologia
doaj   +1 more source

Vascularized joint‐on‐a‐chip: A paradigm shift for arthritis pathophysiology and clinical treatment

open access: yes
Rheumatology &Autoimmunity, EarlyView.
Danli Cui   +6 more
wiley   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

open access: yesArthritis &Rheumatology, Volume 78, Issue 11, Page 2261-2273, November 2026.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy